Seeking Alpha

Ligand lifts guidance on higher-than-expected Captisol sales

  • Ligand Pharmaceuticals (LGND) rallies 6% premarket.
  • The company is out raising its top- and bottom-line guidance for both Q4 and FY13.
  • Q4 and FY13 revenues now seen at $14-14.5M (versus previous guidance of $11-12M) and $48-48.5M (versus previous guidance of $45-46M), respectively.
  • Q4 and FY13 non-GAAP EPS are now seen at $0.31-0.32 (versus previous guidance of $0.22-0.24) and $0.86-0.87 (versus previous guidance of $0.77-0.79), respectively.
  • LGND cites "higher-than-expected sales of Captisol material." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs